Rapid detection of HPV16/18 based on a CRISPR-Cas13a/Cas12a dual-channel system. Issue 48 (30th November 2022)

• Record Type: Journal Article
• Authors: Zheng, Xue; Li, Yuankun; Yuan, Mingzhu; Shen, Yue; Chen, Shuaiyin; Duan, Guangcai
• Is Part Of: Analytical methods. Volume 14:Issue 48(2022)
• Page Start: 5065
• Page End: 5075
• Publication Date: 2022-11-30
• Subjects: Chemistry, Analytic -- Periodicals; Analytical biochemistry -- Periodicals; Chemical laboratories -- Standards -- Periodicals; 543.1905
• DOI: 10.1039/d2ay01536f
• Languages: English
• ISSNs: 1759-9660

Abstract

Abstract : Orthogonal cleavage of DNA and RNA reporters by target-activated Cas12a/Cas13a induces two-colored fluorescence emission (JOE-FAM), which can be detected using a standard fluorometer or observed by a dual-channel visualization detection platform. Abstract : Purpose: cervical cancer is the leading cause of cancer deaths in women in the developing world, with high-risk HPV16 and HPV18 accounting for approximately 70% of all cervical cancers. Early detection of HPV, especially high-risk HPV types, is essential to prevent disease progression. Methods: in this study, we established a highly sensitive and specific nucleic acid assay based on a CRISPR-Cas13a/Cas12a dual-channel system combined with multiplex RAA for rapid detection and typing of HPV16/18, which provides a new idea for cervical cancer screening. To meet the application of field testing, we designed a portable fluorescence imaging assay that can judge the test results directly with the naked eye or through cell phone imaging. Results: the lower limit of detection for both HPV16 and HPV18 based on the CRISPR-Cas12a/Cas13a dual-channel assay was 10 0 copies per μL. The dual-channel assay was validated with 55 clinical samples, showing 97.06% sensitivity, 100% specificity, 100% positive predictive value, and 96.55% negative predictive value. The results of the portable fluorescence imaging assay were fully comparable to those of the real-time fluorescent RAA-based CRISPR-Cas12a/Cas13a dual-channel assay. Conclusions: this developed portable dual gene assay platform may provide new technical support for cervical cancer screening in resource-limited settings.